Hematopoietic prostaglandin D synthase inhibitors for the treatment of Duchenne muscular dystrophy

Brain and Nerve

Volumn 63, Issue 11, 2011, Pages 1261-1269

  Kamauchi, Shinya ^a   Urade, Yoshihiro ^a  

^a OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

Duchenne muscular dystrophy; Hematopoietic prostaglandin D synthase; Polymyotitis; Prostaglandin D 2; Urinary metabolite

Indexed keywords

4 BENZHYDRYLOXY 1 [3 (1H TETRAZOL 5 YL)PROPYL]PIPERIDINE; ENZYME INHIBITOR; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D SYNTHASE INHIBITOR; PROSTAGLANDIN D2; UNCLASSIFIED DRUG;

ANIMAL MODEL; DOG; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE NECROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; NONHUMAN; PROSTAGLANDIN SYNTHESIS; REVIEW; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DEPRESSION, CHEMICAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; MICE; MOLECULAR TARGETED THERAPY; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; PIPERIDINES; PROSTAGLANDIN D2;

EID: 82155187073     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. 2 as a mediator of allergic asthma. Science 287: 2013-2017, 2000
2. 2 inrolved in regulation of physiological sleep. Proc Natl Acad Sci U S A 103: 17949-17954, 2006
3. 2 and sleep/wake regulation. Sleep Med Rev, in press, 2011
4. Smith WL, Urade Y, Jakobsson PJ: Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 111: 5821-5865, 2011
5. Kanaoka Y, Ago H, Inagaki E, Nanayama T, Miyano M, et al.: Cloning and crystal structure of hematopoietic prostaglandin D synthase. Cell 90: 1085-1095, 1997 (Pubitemid 27408522)
6. Urade Y, Eguchi N, Hayaishi O: Lipocalin-type prostaglandin D synthase as an enzymic lipocalin. Landes Bioscience/Eurekah.com, Texas, 2006
7. Moniot B, Declosmenil F, Barrionuevo F, Scherer G, Aritake K, et al.: The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation Development 136: 1813-1821, 2009
8. 2 biosynthesis. J Clin Invest 119: 1477-1488, 2009
9. Inoue T, Irikura D, Okazaki N, Kinugasa S, Matsumura H, et al.: Mechanism of metal activation of human hematopoietic prostaglandin D synthase. Nat Struct Biol 10: 291-296, 2003 (Pubitemid 36418754)
10. Okinaga T, Mohri I, Fujimura H, Imai K, Ono J, et al.: Induction of hematopoietic prostaglandin D synthase in hyalinated necrotic muscle fibers: its implication in grouped necrosis. Acta Neuropathol (Berl) 104: 377-384, 2002 (Pubitemid 36075402)
11. Aritake K, Kado Y, Inoue T, Miyano, M, Urade Y: Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem 281: 15277-15286, 2006 (Pubitemid 43855117)
12. Matsushita N, Aritake K, Takada A, Hizue M, Hayashi K, et al.: Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Jpn J Pharmacol 78: 11-22, 1998 (Pubitemid 28464208)
13. Mohri I, Aritake K, Taniguchi H, Sato Y, Kamauchi S, et al.: Inhibition of prostaglandin D synthase suppresses muscular necrosis. Am J Pathol 174: 1735-1744, 2009
14. 2 in mice and humans. J Biol Chem 283, 1179-1188, 2008
15. Tanaka H, Tsurumura T, Aritake K, Furubayashi N, Takahashi S, et al.: Improvement in the quality of hematopoietic prostaglandin D synthase crystals in a microgravity environment. J Synchrotron Radiat 18: 88-91, 2011
16. Takahashi S, Tsurumura T, Aritake K, Furubayashi N, Sato M, et al.: High-quality crystals of human haematopoietic prostaglandin D synthase with novel inhibitors. Acta Crystallogr Sect F Struct Biol Cryst Commun 66: 846-850, 2010